ABSTRACT
Purpose: To study the awareness of mucormycosis among discharged inpatients after receiving treatment for COVID?19 infection at a tertiary COVID care center in south India. Methods: This was a telephone?based survey conducted using a questionnaire consisting of 38 questions in five sections in the month of June–July 2021. COVID?positive inpatients who had been admitted, treated, and discharged from a government medical college were contacted via phones, and their responses were directly entered into the Google Forms platform. Results: A total of 222 participants were included in the study. Among all the participants, a cumulative 66% of participants had some knowledge of mucormycosis and 98/222 (44%) did not have any idea of mucormycosis in spite of being admitted to the hospital. More than 40% of them reported that their prime source of information was through mass communication. Around 81% of the respondents were aware that it can occur after COVID?19 infection. Among them, only 25 knew that systemic steroids were the main risk factor. Sixty?four out of 124 knew that diabetes is a major risk factor. Fifty percent agreed that a vaccine for COVID can prevent mucormycosis. Conclusion: Such knowledge, attitude, and practice (KAP) studies give us an idea of the impact of the measures taken for educating the public. In this study, a cumulative 66% of participants had some knowledge of mucormycosis and 34.7% were diabetics who had better knowledge and practice scores than non?diabetics. Sixty?six point nine percent felt that it was possible to prevent this condition